Related Experiment Videos
Pivmecillinam in complicated urinary infections failing to respond to conventional therapy
Abstract:
Forty-three patients with a history of recurrent urinary infections, many of whom had renal involvement and had recently failed treatment, were then treated with pivmecillinam (400 mg 8-hourly for seven days). One week after the end of treatment the bacteriological cure rate was 72.1%. During the following four weeks, however, several of the cured patients relapsed, so that the cure rate five weeks after the end of treatment was only 46%. Thus, it is recommended that such patients should begin prophylactic treatment if found to be abacteriuric after the one week follow-up. Pivmecillinam was extremely well tolerated.
Insights
Pivmecillinam treatment for recurrent urinary infections showed a 72.1% cure rate initially. However, relapse rates increased, dropping the cure rate to 46% after five weeks, suggesting a need for prophylactic treatment.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Background:
- Recurrent urinary tract infections (UTIs) pose a significant challenge, often involving renal complications and treatment failures.
- Patients with a history of recurrent UTIs frequently require effective and well-tolerated therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and tolerability of pivmecillinam in patients experiencing recurrent urinary infections.
- To assess the long-term bacteriological cure rates following pivmecillinam treatment in this patient cohort.
Main Methods:
- A cohort of 43 patients with recurrent UTIs, including those with renal involvement and prior treatment failures, were enrolled.
- Patients received pivmecillinam (400 mg) administered every 8 hours for a duration of 7 days.
- Bacteriological assessments were conducted one week and five weeks post-treatment to determine cure rates and identify relapses.
Main Results:
- An initial bacteriological cure rate of 72.1% was observed one week after completing pivmecillinam treatment.
- A significant number of patients relapsed within the subsequent four weeks, leading to a reduced cure rate of 46% at the five-week follow-up.
- Pivmecillinam was found to be extremely well tolerated by the patient group, with no significant adverse events reported.
Conclusions:
- While pivmecillinam demonstrates initial efficacy in treating recurrent UTIs, its effectiveness diminishes over time due to relapse.
- Prophylactic treatment should be considered for patients who achieve abacteriuria after the one-week follow-up to prevent relapses.
- Pivmecillinam is a safe and well-tolerated option for managing recurrent urinary infections, but long-term strategies are necessary.